GRI Bio reports positive Phase 2a immune data for GRI-0621 in IPF

GRI Bio, Inc.

Phase 2a data shows GRI-0621 reduces pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β) and increases anti-fibrotic IFN-γ in BAL and PBMC after 12 weeks.
Study met primary safety/tolerability endpoint; secondary endpoints suggest fibrosis reversal and lung repair, with twice as many subjects with no FVC decline vs standard of care.
35 subjects enrolled, 2:1 randomized to GRI-0621 4.5mg or placebo for 12 weeks; sub-study in 8 subjects examines immune cells in BAL fluid.
Company believes stockholders' equity exceeds $2.5M Nasdaq minimum after December 2025 public offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.